TEL AVIV, Israel--(BUSINESS WIRE)--HAGAR, the developer of GWave, a revolutionary non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, announces today the publication of clinical data demonstrating the device’s impressive accuracy in Diabetes Technology and Therapeutics..

。。

Dr. Irl B. Hirsch, Medical Advisor to HAGAR and Professor of Medicine at the Diabetes Treatment and Teaching Chair in the Division of Metabolism, Endocrinology, and Nutrition at the University of Washington, highlighted findings from recently published HAGAR clinical studies led by Professor Tirosh of Tel Aviv University and Professor Navon of the Weizmann Institute of Science..

哈格的医学顾问、华盛顿大学代谢、内分泌和营养系糖尿病治疗和教学主席的医学教授Irl B.Hirsch博士强调了最近发表的由特拉维夫大学的Tirosh教授和魏茨曼科学研究所的Navon教授领导的哈格临床研究的发现。。

This study, recently published in Diabetes Technology & Therapeutics, highlights the impressive precision of GWave technology. Among 75 participants—including those with type 1 and type 2 diabetes, pregnant women, and individuals without diabetes—97% of GWave readings matched traditional blood glucose tests, with only 3% showing minor deviations.

这项最近发表在《糖尿病技术与治疗学》上的研究突出了GWave技术令人印象深刻的精确度。在包括1型和2型糖尿病患者，孕妇和无糖尿病患者在内的75名参与者中，97%的GWave读数与传统的血糖测试相匹配，只有3%显示出轻微的偏差。

Two separate GWave devices showed identical results, emphasizing their reliability. In detecting low blood sugar, the GWave device accurately tracked levels down to 42 mg/dL, outperforming other CGMs that took 90 minutes to align with GWave and capillary readings..

两个独立的GWave设备显示出相同的结果，强调了它们的可靠性。在检测低血糖时，GWave设备准确地跟踪到42 mg/dL的水平，优于其他需要90分钟才能与GWave和毛细血管读数对齐的CGM。。

A noteworthy aspect of the study involved comparing GWave's performance with a commercial blood glucose monitoring system. The analysis showed that GWave's measurements were highly accurate, with a mean absolute relative difference (MARD) of 6.7%, strongly correlating with capillary glucose levels. GWave's accuracy matched the FreeStyle Lite system, with an R² > 0.99 and 98.8% of results in the ideal range..

该研究的一个值得注意的方面涉及将GWave的性能与商业血糖监测系统进行比较。分析表明，GWave的测量结果非常准确，平均绝对相对差异（MARD）为6.7%，与毛细血管葡萄糖水平密切相关。GWave的精度与FreeStyle Lite系统相匹配，R²>0.99，结果的98.8%在理想范围内。。

Unlike previous attempts by others at RF glucose measurement, GWave effectively eliminates interferences from other dermal components. It emits less radiation than a smartphone and uses a rechargeable battery, eliminating the need for replacements. The planned commercial version will be integrated into a smartwatch for convenience..

。它的辐射比智能手机少，使用可充电电池，无需更换。为了方便起见，计划中的商业版本将集成到智能手表中。。

Integrating GWave into CGM systems promises accurate, noninvasive glucose monitoring, benefiting those needing precise insulin dosing and real-time glycemic event detection. This technology also addresses adherence challenges in type 2 and gestational diabetes, potentially improving outcomes and quality of life.

将GWave整合到CGM系统中有望实现准确，无创的血糖监测，有利于那些需要精确胰岛素剂量和实时血糖事件检测的人。这项技术还解决了2型糖尿病和妊娠糖尿病的依从性挑战，可能会改善预后和生活质量。

Noninvasive CGM systems like GWave could enhance diabetes screening and management, enabling earlier intervention and better health results. In addition, CGM devices have increased in popularity over the years for those in the wellness space who may be looking at preventative measures for long-term health.

像GWave这样的非侵入性CGM系统可以增强糖尿病筛查和管理，从而实现早期干预和更好的健康结果。此外，多年来，CGM设备在那些可能正在寻求长期健康预防措施的健康领域越来越受欢迎。

GWave offers an effective, non-invasive manner to help those who may be pre-diabetic or those individuals without diabetes reduce their risk with greater knowledge of their overall health and assist doctors with more accurate information..

GWave提供了一种有效的、非侵入性的方式，帮助那些可能患有糖尿病前期的人或那些没有糖尿病的人通过对其整体健康的更多了解来降低风险，并为医生提供更准确的信息。。

HAGAR's breakthrough designation by the FDA in 2021 is a testament to the company's success and ongoing commitment to bringing cutting-edge technology to the market. This designation is pivotal as HAGAR continues to advance its clinical research and prepare for further studies in the United States and Israel in the latter half of 2024..

哈格于2021年被美国食品和药物管理局（FDA）授予突破性称号，这证明了该公司的成功以及将尖端技术推向市场的持续承诺。随着夏甲继续推进其临床研究，并为2024年下半年在美国和以色列的进一步研究做好准备，这一指定至关重要。。

'We are excited to share our latest findings with the medical community,' said Dr. Irl B. Hirsch. 'The accuracy and reliability of the GWave device, as demonstrated in our recent study, are promising indicators of its potential to transform diabetes management. This technology represents a significant step forward in providing patients with a more accessible and non-invasive method to monitor their glucose levels.'.

“我们很高兴能与医学界分享我们的最新发现，”伊尔·赫希博士说正如我们最近的研究所证明的那样，GWave设备的准确性和可靠性是其改变糖尿病管理潜力的有希望的指标。。

For more information on Hagar and the GWave technology, visit here.

有关Hagar和GWave技术的更多信息，请访问此处。

About HAGAR N.I.G

关于HAGAR N.I.G

HAGAR N.I.G. (Non-invasive Glucose Monitoring) is the developer of GWave, the first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood. GWave First Generation is a third of the size of a smartphone, which sends glucose readings to the user via a smartphone app that can easily be shared with their healthcare provider.

HAGAR N.I.G.（无创血糖监测）是GWave的开发人员，GWave是第一种使用射频波测量血液中葡萄糖水平的无创连续血糖监测技术。GWave第一代是智能手机的三分之一大小，它通过智能手机应用程序向用户发送葡萄糖读数，该应用程序可以很容易地与他们的医疗保健提供者共享。

GWave’s final product will be a sensor integrated into a smartwatch..

GWave的最终产品将是集成到智能手表中的传感器。。

For more information, visit: https://www.Hagartech.com/

For more information, visit: https://www.Hagartech.com/